Orphan drug designation granted to RiVax for prevention of ricin intoxication

Soligenix was granted orphan drug designation by the FDA for RiVax for the treatment of ricin intoxication. Results of the Phase 1A clinical trial of RiVax indicated that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure. A Phase 1B clinical trial, to evaluate a more potent formulation of RiVax, remains ongoing.

RiVax is a proprietary ricin toxin vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals.

For more information call (609) 538-8200 or visit www.soligenix.com.